Bridgeway Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Bridgeway Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Hold	149,900	–	–	0.02%	673
2026 Q1	$1.29M	Sell	149,900 -25,000	-14%	-$208K	0.03%	646
2025 Q4	$1.64M	Hold	174,900	–	–	0.03%	595
2025 Q3	$1.05M	Buy	174,900 +112,000	+178%	+$448K	0.02%	690
2025 Q2	$193K	Sell	62,900 -73,400	-54%	-$182K	﹤0.01%	969
2025 Q1	$263K	Buy	136,300 +56,300	+70%	+$166K	0.01%	864
2024 Q4	$299K	Buy	+80,000	New	+$383K	0.01%	923

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Bridgeway Capital Management's KYTX Position: Q2 2026 in Review

Bridgeway Capital Management held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 149,900 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #673.

Bridgeway Capital Management first reported a position in KYTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.64M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

Bridgeway Capital Management held 149,900 shares of Kyverna Therapeutics worth $1.34M as of Q2 2026.
Bridgeway Capital Management left its Kyverna Therapeutics share count unchanged in Q2 2026.
Kyverna Therapeutics made up 0.02% of Bridgeway Capital Management's portfolio in Q2 2026, its #673 holding.
Bridgeway Capital Management first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 7 quarters since.
Bridgeway Capital Management's Kyverna Therapeutics position peaked at $1.64M in Q4 2025.
120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.